Efficacy and toxicity evaluation
death, Tumor, toxicity, Tumors, Toxicity, Cancer
TUMORS, DISEASE PROGRESSION, TUMOR, CANCER
All the patients were followed up until disease progression or death. Tumor response was evaluated by imaging every two cycles of treatment (every 6 weeks) according to the Response Evaluation Criteria in Solid Tumors guidelines version 1.1 (RECIST1.1). Any toxicity was observed and graded according to the National Cancer Institute Common Toxicity Criteria Version 4.0 (NCI CTCAE 4.0). All the recorded data were evaluated and checked by our clinicians. Other assessments, including physical examination, measurement of vital signs, complete blood count, biochemistry, and routine urine analysis, were also performed after every two cycles of treatment.